Sun Biopharma, Inc.

MN · Biotech · Public

SBP-101, a small molecule drug that inhibits pancreatic enzyme activation to treat acute pancreatitis

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of SBP-101 for the Treatment of Acute Pancreatitis$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3195VIOMEDIX, LLC——
3196BIOTRACKING LLC——
3197Nashville Clinic, LP—$800K
3198Sun Biopharma, Inc.——
3199Jortan Pharmaceuticals Inc.——
3200TheraCea Pharma LC——
3201SAHANE BIOTECH INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Dosing Regimens And Methods For Treating Cancerapplication
  • Methods For Producing (6S,15S)-3,8,13,18-TETRAAZAICOSANE-6,15-DIOLapplication
  • Methods For Producing (6S,15S)-3,8,13,18-TETRAAZAICOSANE-6,15-DIOLapplication
  • Compositions And Methods For Treating Pancreatitisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.